In a pair of articles published in Lancet Gastroenterology & Hepatology, scientists lay out the case for why we should expand ...

Hepatitis B virus, a killer of more than one million people each year, is a notoriously wily virus, often lingering and ...

Chronic hepatitis B treatment relies on nucleoside or nucleotide analogue drugs that suppress hepatitis B virus (HBV) ...

A study just published on Eurosurveillance has found evidence of substantial lifetime exposure to hepatitis B and C viruses in Ukraine in a 2021 nationwide, representative sample of the population, ...

Let’s Break It Down,” emphasize the urgent need to remove barriers to prevention, testing, and treatment to reduce liver cancer and eliminate hepatitis by 2030.

TherVacB, a novel therapeutic vaccine for chronic hepatitis B developed under the leadership of Helmholtz Munich, has entered its first clinical trial in patients. Following a successful phase 1a ...

Discover a study comparing HBV- and alcohol-related ACLF, highlighting distinct clinical profiles and the need for aetiology-specific treatment strategies.

Chronic hepatitis B virus (HBV) is an under-recognised global health threat that affects over 250 million individuals, of whom 80% reside in low-income and middle-income countries (LMICs). HBV causes ...

We read with great interest the recent article by Tseng et al evaluating hepatitis B surface antigen (HBsAg) levels as a ...